Aptcash Enterprises
Parel, Mumbai, Maharashtra
GST No. 27BDTPM3418D1ZF
TrustSEAL Verified
View Mobile No.
SEND EMAIL

Oncology Injection

Wholesale Trader of a wide range of products which include enzalutamide glenza 40mg capsule and lenvatinib lenvima 4mg capsule.

Enzalutamide Glenza 40mg Capsule

Enzalutamide Glenza 40mg Capsule
  • Enzalutamide Glenza 40mg Capsule
  • Enzalutamide Glenza 40mg Capsule
  • Enzalutamide Glenza 40mg Capsule
  • Enzalutamide Glenza 40mg Capsule
  • Enzalutamide Glenza 40mg Capsule
  • Enzalutamide Glenza 40mg Capsule
Get Best Quote
Approx. Price: Rs 1,600 / PieceGet Latest Price

Product Details:

Type Of SurgeryUrological Surgery
ManufacturerGlenmark
Treatmentmetastatic castration-resistant prostate cancer (mCRPC),nonmetastatic castration-resistant prostate
Dose Strength40mg once per day (four capsules).
Categoryprostate cancer
CompositionEnzalutamide
DrugEnzalutamide
Generic NameEnzalutamide
Dosage FormOral
Packaging Type28cap x 4 (112 cap) 40mg
Packaging Size40mg capsule for 28cap x 4 (112 cap) per month therapy
Therapeutic Usesmetastatic castration-resistant prostate cancer (mCRPC),nonmetastatic castration-resistant prostate
Interactionsoderate to strong inducer of multiple cytochrome P450 enzymes including CYP3A4,CYP2C9,and CYP2C19
Side Effectasthenia,back pain,diarrhea,arthralgia,and hot flashes.Rarely,it can cause seizures
Pregnancy & breast feedingEnzalutamide is contraindicated in women during pregnancy.It may cause fetal harm.
Strength40mg capsule
FormEnzalutamide is provided in the form of 40 mg Capsule.It is taken orally

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer.It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

Side effects of enzalutamide when added to castration include asthenia, back pain, diarrhea, arthralgia, and hot flashes.Rarely, it can cause seizures.It has a high potential for drug interactions.Enzalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents the effects of these hormones in the prostate gland and elsewhere in the body.

Enzalutamide was first described in 2006, and was introduced for the treatment of prostate cancer in 2012. It was the first second-generation NSAA to be introduced.[11] The medication is available throughout the world.

Medical uses
Prostate cancer

Enzalutamide is clinically effective in the treatment of mCRPC.[13] An up to 89% decrease in serum prostate specific antigen (PSA) levels have been reported after a month of taking the drug. PSA level decreased more than 50% in 40 of 65 chemo-naive patients and 38 of 75 chemotherapy-treated patients.Median time to radiographic progression was 56 weeks for chemo-naive patients and 25 weeks for the post-chemotherapy population.

Medivation, the developer of enzalutamide, conducted an international phase III trial that began in September 2009 known as AFFIRM. The aim of this trial was determine the safety and effectiveness of enzalutamide in patients who have previously failed chemotherapy treatment with docetaxel.

Another phase III trial known as PREVAIL is investigating[when?] the effectiveness of enzalutamide with patients who have not yet received chemotherapy.[19] On October 22, 2013, Medivation and Astellas announced that the PREVAIL trial met both co-primary endpoints of overall survival, with a 30% reduction in the risk of death compared with placebo (hazard ratio = 0.7; 95% confidence interval, range of 0.59-0.83), and radiographic progression-free survival, with an 81% reduction in risk of radiographic progression or death compared with placebo (hazard ratio = 0.19); 95% confidence interval, 0.15-0.23). In addition, a phase II trial began in March 2011 comparing enzalutamide with bicalutamide in prostate cancer patients who have progressed while on gonadotropin-releasing hormone (GnRH) analogue therapy (e.g., leuprorelin) or surgical castration.Addition of Enzalutamide with testosterone suppression in men with castration-resistant prostate cancer showed better survival compared to standard nonsteroidal antiandrogen therapy.
Other uses

Enzalutamide can be used as an antiandrogen in feminizing hormone therapy for transgender women.

Contraindications
Enzalutamide is contraindicated in women during pregnancy.It may cause fetal harm.

Side effects

Notable side effects of enzalutamide seen in clinical trials have included gynecomastia, breast pain/tenderness, fatigue, diarrhea, hot flashes, headache, sexual dysfunction, and, less commonly, seizures. Other "common" side effects reported in clinical trials have included neutropenia, visual hallucinations, anxiety, cognitive disorder, memory impairment, hypertension, dry skin, and pruritus (itching).Enzalutamide monotherapy is regarded as having a moderate negative effect on sexual function and activity, significantly less than that of GnRH analogues but similar to that of other NSAAs such as bicalutamide.
Request
Callback


Additional Information:

  • Packaging Details: Enzalutamide is provided in the form of 40 mg Capsule.It is taken orally at a dosage of 160 mg once per day (four capsules).
Yes! I am Interested

Lenvatinib Lenvima 4mg Capsule

Lenvatinib Lenvima 4mg Capsule
  • Lenvatinib Lenvima 4mg Capsule
  • Lenvatinib Lenvima 4mg Capsule
  • Lenvatinib Lenvima 4mg Capsule
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength4mg
Packaging Size4mg,2 x 10 Capsule
BrandLenvima
CompositionLenvatinib
ManufacturerEisai Pharma
Treatmentthyroid cancer that is either locally recurrent or metastatic,progressive,and did not respond to t
FormCapsule

Lenvatinib (Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

Medical uses
Lenvatinib is approved (since 2015) for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).

In May 2016, the US FDA approved it (in combination with everolimus) for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.

The drug is also approved in the US and in Europe for hepatocellular carcinoma that cannot be removed surgically in patients who have not received cancer therapy by mouth or injection.

Adverse effects
Hypertension (high blood pressure) was the most common side effect in studies (73% of patients, versus 16% in the placebo group), followed by diarrhoea (67% vs. 17%) and fatigue (67% vs. 35%). Other common side effects included decreased appetite, hypotension (low blood pressure), thrombocytopenia (low blood platelet count), nausea, muscle and bone pain.

Interactions
As lenvatinib moderately prolongs QT time, addition of other drugs with this property could increase the risk of a type of abnormal heart rhythm, namely torsades de pointes. No relevant interactions with enzyme inhibitors and inducers are expected.

Mechanism of action
Lenvatinib acts as a multiple kinase inhibitor. It inhibits the three main vascular endothelial growth factor receptors VEGFR1, 2 and 3, as well as fibroblast growth factor receptors (FGFR) 1, 2, 3 and 4, platelet-derived growth factor receptor (PDGFR) alpha, c-Kit, and the RET proto-oncogene. Some of these proteins play roles in cancerogenic signalling pathways. VEGFR2 inhibition is thought to be the main reason for the most common side effect, hypertension.

Pharmacokinetics
Lenvatinib is absorbed quickly from the gut, reaching peak blood plasma concentrations after one to four hours (three to seven hours if taken with food). Bioavailability is estimated to be about 85%. The substance is almost completely (98–99%) bound to plasma proteins, mainly albumin.
Lenvatinib is oxidized by cytochrome P450 enzymes (CYP), and further metabolized to the quinolinones M2' and M3' by aldehyde oxidase (AO).

Lenvatinib is metabolized by the liver enzyme CYP3A4 to desmethyl-lenvatinib (M2). M2 and lenvatinib itself are oxidized by aldehyde oxidase (AO) to substances called M2' and M3', the main metabolites in the feces. Another metabolite, also mediated by a CYP enzyme, is the N-oxide M3. Non-enzymatic metabolization also occurs, resulting in a low potential for interactions with enzyme inhibitors and inducers.

Terminal half-life is 28 hours, with about two thirds being excreted via the feces, and one quarter via the urine.

Chemistry
Lenvatinib is used in form of the mesylate salt (CAS number 857890-39-2 ).History
A phase I clinical trial in cancer patients was performed in 2006. A phase III trial treating thyroid cancer patients started in March 2011.
Lenvatinib was granted orphan drug status for treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.
In February 2015, the U.S. FDA approved lenvatinib for treatment of progressive, radioiodine refractory differentiated thyroid cancer. In May 2015, European Medicines Agency (EMA) approved the drug for the same indication.
In May 2016, the FDA approved it (in combina.with everolimus) for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.
In August 2018, the FDA lenvatinib for first-line treatment of patients with unresectable hepatocellular carcinoma.
Request
Callback


Additional Information:

  • Packaging Details: 4mg, 2 x 10 capsule
Yes! I am Interested
X

Explore More Product



Reach Us
Aptcash Enterprises (Proprietor)
Aptcash Enterprises
Shop No. 7, B Wing, Nirmala Niwas, Aai Mai Merwanji Road
Parel, Mumbai - 400012, Maharashtra, India


Call Us
View Mobile No.


Send E-mailSend SMS